daclizumab


Also found in: Wikipedia.

daclizumab

 [dah-kliz´u-mab]
an immunosuppressant used to prevent acute organ rejection in renal transplant patients; administered intravenously.

daclizumab

/da·cliz·u·mab/ (dah-kliz´u-mab) an immunosuppressant used to prevent acute organ rejection in renal transplant patients.

daclizumab

an immunosuppressant.
indications It is used to help prevent acute allograft rejection in renal transplant patients.
contraindications Known hypersensitivity to this drug contraindicates its use.
adverse effects Life-threatening effects are pulmonary edema, tachycardia, thrombosis, renal tubular necrosis, and hydronephrosis. Other adverse effects include headache, prickly sensation, coughing, atelectasis, congestion, constipation, abdominal pain, pyrosis, hypertension, bleeding, oliguria, dysuria, renal damage, and impaired wound healing. Common side effects include chills, tremors, dyspnea, wheezing, vomiting, nausea, and diarrhea.

daclizumab

Dacliximab, Zenapax® Transplant medicine A monoclonal antibody used with other agents to ↓ transplant-related GVHD and organ rejection in kidney and liver graft recipients, and Pts with treatment refractory psoriasis, uveitis, tropical spastic paraparesis and some leukemias. See Kidney transplant.

daclizumab

A humanized monoclonal antibody against the interleukin-2 receptor. It is used to decrease the risk of organ rejection in kidney and heart transplants.
References in periodicals archive ?
Mostly thymoglobulin, alemtuzumab, basiliximab, and daclizumab are used for this induction.
Patients received either Thymoglobulin or daclizumab and showed a lower incidence of treatment failure as measured by the composite endpoint 12 months following transplantation.
Additionally, daclizumab (Zenapax), which was approved several years ago for prophylaxis of acute organ rejection in patients receiving renal transplants, was approved for multiple sclerosis treatment (Zinbryta) last year, and sofosbuvir (Sovaldi), which was approved in 2013 for the treatment of hepatitis C virus, is now combined with velpatasvir (Epclusa) to treat all six major forms of hepatitis C.
33) Many other biologies have also been trialled in patients who have uveitis including: etanercept, adalimumab and daclizumab.
Zinbryta[TM], the brand name for daclizumab produced by Biogen and AbbVie, is an immune-modulating therapy taken by self-injection under the skin every four weeks.
Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells.
De ellos, cuatro tenian sindrome de VKH; uno era resistente al infliximab, uno resistente al daclizumab y los otros dos resistentes a los inmunosupresores convencionales.
These include tocilizumab, an inhibitor of proinflammatory cytokine interleukin (IL)-6; rituximab, an antiCD-20 monoclonal antibody; anakinra, an IL-1 antagonist; daclizumab, an IL-2 antagonist; and abatacept, a cytotoxic T lymphocyte-associated antigen 4 fusion protein that inhibits T cell co-stimulation.
Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: Rejection and infection rates in 40 recipients during the early postoperative period.
All patients received induction with interleukin-2 receptor blocker daclizumab (100 mg/d) on the day of transplantation and 10 days after transplantation or basiliximab (40 mg at days 0 and 4), followed by triple therapy with prednisone, tacrolimus, or cyclosporine and mycophenolate mofetil.
Monoclonal Infix Target Infix Source Suffix Antibody Name Transtuzumab Gemtuzumab tu-Tumor zu-humanized -mab Infliximab Basiliximab li-Immune system xi-chimeric Omalizumab Daclizumab li-Immune cells zu-humanised Palivizumab vi-viral zu-humanised Denosumab s-Bone cells u-human Rituximab tu-Tumor xi-chimeric Icrucumab c-cardiovascular u-human Guselkumab k-interleukin u-human Fosinumab n-nerve u-human Blintumomab tum-Tumor cells o-murine lymphocytes